# INTERVIEW: Optibiotix Health Plc Deal with Sacco the first of many

- Link: https://www.directorstalkinterviews.com/interview-optibiotix-health-plc-deal-sacco-first-many/412725229
- Published: 2017-03-09T14:01:21+00:00
- Author: Giles Arbor

**Optibiotix Health Plc** (LON:OPTI) CEO Stephen O’Hara talks to DirectorsTalk about
its European manufacturing, supply and profit sharing agreement with Sacco S.r.l.
Stephen explains tells us more about the agreement and its pipeline for other agreements
like this.

Optibiotix Health Plc is a life sciences company developing a range of products 
to modify the human microbiome. The Company’s principal activity is research and
development into microbiome modulators. It operates in UK segment. The Company has
a pipeline of microbiome modulators that can impact on lipid and cholesterol management,
energy harvest and appetite suppression. The development pipeline is operated by
its OptiScreen and OptiBiotic platform technologies designed to identify metabolic
pathways and compounds that impact on human physiology. Its Optiscreen is a screening
and optimization technology platform designed to identify microbes within the human
microbiome with metabolic pathways, which can interact with human physiological 
processes. Its OptiBiotic is a platform technology, which generates compounds and
screens them for their ability to modulate the human microbiome and its microbial
end products. Its platforms are applicable across a range of other human diseases.

Share on:
